$SAJ

SARATOGA INVESTMENT CORP. (SAJ): Results of Operations and Financial Condition

SARATOGA INVESTMENT CORP. (SAJ) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea029727501ex99-1.htm PRESS RELEASE DATED JULY 7, 2026 OF SARATOGA INVESTMENT CORP Exhibit 99.1 Saratoga Investment Corp. Announces Fiscal First Quarter 2027 Financial Results Reports Quarterly Asset Growth of 1.6% and Net Originations of $31 Million, Including Two New

Original reporting
Published Jul 7, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$SAJ
Bearish
high confidence
Mentioned
$SAJ
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SAJBearishMed
01

Why it matters

Key decision inputs for traders are the sequential changes in NAV per share (-4.9%), adjusted NII per share ($0.47 vs $0.53), and the credit/valuation drivers (named markdowns including Pepper Palace to zero; Exigo on red watchlist; non-accrual status). The company also reiterates/announces a base monthly dividend of $0.25 per share (=$0.75 quarterly).

02

Market read

The filing updates the market on income generation (adjusted NII), balance-sheet valuation (NAV per share), and credit quality/markdown drivers—core variables for BDC valuation and dividend expectations.

03

What to watch

Dividend durability may be less threatened than NAV suggests because the filing attributes much of the NAV reduction to unrealized depreciation and specific credits (Pepper Palace to zero; Exigo on red watchlist) rather than broad credit deterioration; traders should separate realized income under-earning from longer-term portfolio valuation trends.

Relevance 7/10Novelty 6/10Timing: after-hours/filing today (July 7, 2026) for fiscal first quarter 2027 ended May 31, 2026

Background

This is an SEC 8-K with an attached press release reporting Saratoga Investment’s fiscal first quarter 2027 financial results (ended May 31, 2026) and key portfolio/credit metrics.

Company-level read

Ticker impact

$SAJBearishHigh confidence
Context

Saratoga Investment reported fiscal Q1 2027 results: NAV per share fell to $23.23 from $24.42 and adjusted NII per share dropped to $0.47.

Expected impact

Near-term downside bias versus prior quarter expectations, with focus on dividend coverage and the extent of further NAV pressure from non-accrual/“red watchlist” credits.

Evidence & confidence

The 8-K includes specific datapoints (NAV per share -4.9% sequential; adjusted NII per share $0.47 vs $0.53; non-accruals at 0.0% of fair value but 1.2% of cost; named credits Pepper Palace written down to zero and Exigo on red watchlist). These are direct inputs to BDC valuation and income durability.

Market effects

Provides a datapoint on private credit/BDC pressure: declining short-term rates and tight spreads are explicitly cited as headwinds to adjusted NII.

Primarily US-listed BDC sentiment; limited direct regional spillover beyond private credit income expectations.

Macro-linked (rates/spreads) but company-specific; likely modest read-through to global private credit risk appetite.

Counterpoint

Despite NAV and adjusted NII declines, the company highlights core fair value within 0.2% of cost and a 0.0% of fair value non-accrual rate, suggesting the markdowns may be more idiosyncratic than systemic.

Key entities

  • Saratoga Investment Corp.

    BDC reporting fiscal first quarter 2027 results, including NAV per share, adjusted NII, dividend, and portfolio credit/valuation changes.

  • Pepper Palace

    Named credit written down to zero and placed on non-accrual during the quarter.

  • Exigo

    Named credit carried at $17.3 million (70% of cost) and on red watchlist status.

Related articles

$DGHighAI 9/10

Dollar General gets Q2 boost from tariff refunds, delivery

Dollar General reported Q2 net income rose 33.8% to $550.3M, with sales up 5.2% to $11.3B, driven by tariff refunds and delivery growth. The company raised its full-year outlook, now expecting sales growth of 4% to 4.3% and EPS of $7.80 to $8.00. It also expanded its $1 Value Valley sections to 9,000 stores, boosting comp-store sales.

$WSMMedAI 8/10

Williams-Sonoma Tops Gordon Haskett’s Home Vertical Rankings

Gordon Haskett ranked Williams-Sonoma (WSM) top in the home vertical sector, citing strong Q2 results and improved outlook. The firm maintained a Buy rating with a $260 price target, based on 24x fiscal 2027 EPS estimate of $10.75. WSM reported Q2 revenue of $1.96B and EPS of $2.10, with same-store sales up 6.2% and operating margin at 17.3%. The company raised fiscal 2026 guidance for same-store sales and operating margin.

$DYHigh

Why Dycom Industries Stock Is Plummeting This Week

Dycom Industries (NYSE: DY) reported Q2 2027 revenue of $2.01B, beating estimates, but its adjusted EBITDA margin shrank to 13.6% from 14.9% YoY. Analysts like KeyBanc and Cantor Fitzgerald lowered price targets. Shares fell 21.6% this week. The company's backlog grew to $12.2B, and free cash flow rose to $37.9B.

$PLABHighAI 8/10

Photronics (PLAB) Crushed Earnings Estimates, Then The Stock Gave It Back

Photronics (PLAB) reported fiscal Q3 revenue of $216.0M, beating estimates, with adjusted earnings of $0.50 per share. Despite an initial 27.1% stock surge, shares settled up only 4%. High-end IC business revenue rose 5% YoY, reaching a record 44% of total IC revenue. Guidance for Q4 revenue is $207M-$227M, with adjusted earnings per share ranging from $0.48 to $0.56. Short interest is at 10.61% of the float, indicating significant bearish sentiment.

$BBYHigh

Could tech startups rescue rural healthcare?

Best Buy raised its fiscal year outlook after reporting a 4.1% increase in comparable sales in Q2. Meanwhile, states are investing in tech startups to address rural healthcare challenges, despite the unproven nature of these companies.